BRAF and melanoma: Melanoma is a highly mutated malignancy with poor prognosis.20 About half of all melanoma patients harbor an activating BRAF mutation.21 Our meta‐analysis suggests that BRAF inhibition in combination with MEK has a protective effect compared to BRAF inhibition alone owing to the better overall survival, response rate and reduction the risk of death events.